Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis
10.4049/jimmunol.178.8.5288 · doi-reference
Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist
10.1038/s41366-021-00955-7 · doi-reference
Multi-pathway-driven hepatic protection: Semaglutide combined with HIIT counteracts diabetic liver injury in db/db mice
10.1111/jdi.70174 · doi-reference
Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
10.3389/fendo.2022.1046130 · doi-reference
Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases
10.1093/cvr/cvu035 · doi-reference
Properties of the permeability transition pore in mitochondria devoid of cyclophilin D
10.1074/jbc.c500089200 · doi-reference
Liver cyclophilin D deficiency inhibits the progression of early NASH by ameliorating steatosis and inflammation
10.1016/j.bbrc.2022.01.059 · doi-reference
Intracellular and extracellular Cyclophilin a promote cardiac fibrosis through TGF-β signaling in response to angiotensin Ⅱ
10.1016/j.bcp.2024.116271 · doi-reference
Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease
10.3390/ijms25052961 · doi-reference
Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin
10.1016/j.ejphar.2022.175397 · doi-reference
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis
10.1186/s12902-024-01775-2 · doi-reference
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
10.1136/gutjnl-2023-330962 · doi-reference
GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score-matched population-based cohort study
10.1016/j.diabres.2025.112407 · doi-reference
Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice
10.1096/fj.14-268425 · doi-reference
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels
10.14309/ajg.0000000000000388 · doi-reference
Fiji: an open-source platform for biological-image analysis
10.1038/nmeth.2019 · doi-reference
Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis
10.3389/fphar.2019.01129 · doi-reference
The carbon tetrachloride model in mice
10.1177/0023677215571192 · doi-reference
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
10.1002/hep.30626 · doi-reference
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
10.1016/j.jhep.2018.03.011 · doi-reference
Mechanisms of NAFLD development and therapeutic strategies
10.1038/s41591-018-0104-9 · doi-reference
Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model
10.1371/journal.pone.0298211 · doi-reference
Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH
10.1371/journal.pone.0301711 · doi-reference
Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis
10.1016/j.yjmcc.2012.03.004 · doi-reference
Cyclophilin Inhibition Protects Against Experimental Acute Kidney Injury and Renal Interstitial Fibrosis
10.3390/ijms22010271 · doi-reference
The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
10.3390/v15102099 · doi-reference
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
10.1124/jpet.119.261099 · doi-reference
Cyclophilin inhibition as a strategy for the treatment of human disease
10.3389/fphar.2024.1417945 · doi-reference
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
10.1016/j.jhep.2010.09.032 · doi-reference
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
10.1016/j.molmet.2020.101102 · doi-reference
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
10.1002/hep.28431 · doi-reference
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · doi-reference
